应用5G技术实施实时远程视网膜激光光凝治疗糖尿病视网膜病变
一项前瞻性研究纳入6例(9眼)增殖性或重度非增殖性糖尿病视网膜病变患者,由北京视网膜专家通过5G网络对1200公里外浙江湖州的患者进行实时远程激光光凝。所有眼均顺利完成治疗,无 noticeable 延迟,单次全视网膜光凝平均913个光斑。结论提示5G实时远程激光光凝治疗糖尿病视网膜病变可行,但需进一步与标准治疗比较视力或安全性结局。
要点
- 5G实时远程激光光凝治疗糖尿病视网膜病变在6例(9眼)中可行,无 noticeable 延迟。
- 单次全视网膜光凝平均(SD)光斑数为913(243)个/眼。
- 基线平均(SD)logMAR为0.32(0.20)(Snellen等效20/30)。
核心结论
- 5G实时远程视网膜激光光凝治疗糖尿病视网膜病变是可行的,为远程患者提供治疗新范式。
研究设计与样本
- 前瞻性研究,纳入6例(9眼)增殖性或重度非增殖性糖尿病视网膜病变患者,由北京视网膜专家通过5G网络对1200公里外浙江湖州患者进行实时远程激光光凝。
主要发现
- 所有眼均完成远程视网膜激光光凝操作,治疗过程中无 noticeable 延迟。
- 单次全视网膜光凝平均(SD)光斑数为913(243)个/眼。
- 患者平均(SD)年龄53.7(13.6)岁(范围32-67岁),平均(SD)糖尿病病程14.3(6.4)年(范围3-20年)。
- 基线平均(SD)logMAR为0.32(0.20)(Snellen等效20/30)。
临床怎么用
- 对于偏远地区增殖性或重度非增殖性糖尿病视网膜病变患者,可考虑通过5G网络实施实时远程激光光凝治疗。
局限性
- 样本量小(6例9眼),需进一步研究比较该方法与当前标准治疗在视力或安全性结局上的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Interest in teleophthalmology has been growing, especially during the COVID-19 pandemic. The advent of fifth-generation (5G) wireless systems has the potential to revolutionize teleophthalmology, but these systems have not previously been leveraged to conduct therapeutic telemedicine in the ophthalmology field. OBJECTIVE: To assess the feasibility of 5G real-time laser photocoagulation as a telemedicine-based treatment for diabetic retinopathy (DR). DESIGN, SETTING, AND PARTICIPANTS: This was a prospective study involving a retinal specialist from the Peking Union Medical College Hospital in Beijing, China, who performed online 5G real-time navigated retinal laser photocoagulation to treat participants with proliferative or severe nonproliferative DR who had been recruited in the Huzhou First People's Hospital in Zhejiang Province, China, located 1200 km from Beijing from October 2019 to July 2020. INTERVENTIONS: These teleretinal DR and laser management procedures were conducted using a teleophthalmology platform that used the videoconference platform for teleconsultation, after which telelaser planning and intervention were conducted with a laser system and a platform for remote computer control, which were connected via 5G networks. MAIN OUTCOMES AND MEASURES: Diabetic eye prognosis and the real-time laser therapy transmission speed were evaluated. RESULTS: A total of 6 participants (9 eyes) were included. Six eyes were treated via panretinal photocoagulation alone, while 1 eye underwent focal/grid photocoagulation and 2 eyes underwent both panretinal photocoagulation and focal/grid photocoagulation. The mean (SD) age was 53.7 (13.6) years (range, 32-67 years). The mean (SD) duration of diabetes was 14.3 (6.4) years (range, 3-20 years). The mean (SD) logMAR at baseline was 0.32 (0.20) (20/30 Snellen equivalent). Retinal telephotocoagulation operations were performed on all eyes without any noticeable delay during treatment. The mean (SD) number of panretinal photocoagulation laser spots per eye in 1 session was 913 (243). CONCLUSIONS AND RELEVANCE: This study introduces a novel teleophthalmology paradigm to treat DR at a distance. Applying novel technologies may continue to ensure that remote patients with DR and other conditions have access to essential health care. Further studies will be needed to compare this approach with the current standard of care to determine whether visual acuity or safety outcomes differ.
引用
- Chen H, Pan X, Yang J, et al. Application of 5G Technology to Conduct Real-Time Teleretinal Laser Photocoagulation for the Treatment of Diabetic Retinopathy. JAMA Ophthalmol. 2021. PMID: 34236391. doi:10.1001/jamaophthalmol.2021.2312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。